Pipeline

Passion for Discovery

pipeline

Agios has leveraged its core capabilities in cellular metabolism and precision medicine to build a product engine that is focused in the therapeutic areas of cancer and rare genetic diseases.

CANDIDATE
Early Stage Clinical Development
Late Stage Development
FILED
R/R AML
Phase 3
R/R AML
Phase 1/2
Frontline AML
Phase 1b 7+3 Combo
Frontline AML
Phase 1/2 VIDAZA® Combo
  • Celgene has worldwide development and commercialization rights.

    Agios has U.S. co –promotion and royalty rights.

  • Enasidenib
Frontline AML
Phase 3 (1H' 17)
R/R AML
Phase 1 Dose Escalation
Expansion Cohorts
Frontline AML
Phase 1b 7+3 Combo
Frontline AML
Phase 1/2 VIDAZA® Combo
Solid Tumors
Phase 1 Dose Escalation
Expansion Cohorts
Cholangiocarcinoma
Phase 3
Solid Tumors
Phase 1 Dose Escalation
  • Joint worldwide collaboration with Celgene.

  • AG-881

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.